MARKET

UPB

UPB

UpStream Bio Inc.
NASDAQ
9.11
+0.02
+0.22%
After Hours: 9.11 0 0.00% 17:20 05/11 EDT
OPEN
9.20
PREV CLOSE
9.09
HIGH
9.60
LOW
9.05
VOLUME
618.88K
TURNOVER
--
52 WEEK HIGH
33.68
52 WEEK LOW
7.25
MARKET CAP
495.77M
P/E (TTM)
-3.4202
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at UPB last week (0504-0508)?
Weekly Report · 11h ago
Upstream Bio's Verekitug Data Will Either Validate the Mechanism or Expose the Limitation
Barchart · 05/04 16:32
Weekly Report: what happened at UPB last week (0427-0501)?
Weekly Report · 05/04 09:47
Weekly Report: what happened at UPB last week (0420-0424)?
Weekly Report · 04/27 09:48
Weekly Report: what happened at UPB last week (0413-0417)?
Weekly Report · 04/20 09:46
Upstream Bio Announces Presentation Of New Data From Phase 2 VIBRANT Trial At American Thoracic Society Meeting On May 18
Benzinga · 04/17 11:07
Upstream Bio to present new data from Phase 2 Vibrant trial of Verekitug
TipRanks · 04/17 11:07
Upstream Bio to present Phase 2 VIBRANT verekitug data at ATS 2026 conference
PUBT · 04/17 11:01
More
About UPB
Upstream Bio, Inc. is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is developing verekitug, the only known antagonist in clinical development, that targets the receptor for thymic stromal lymphopoietin (TSLP), a cytokine which is a clinically validated driver of inflammatory response positioned upstream of multiple signaling cascades that affect a variety of immune mediated diseases. It has advanced this highly potent monoclonal antibody into separate phase II trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and plans to initiate development in chronic obstructive pulmonary disease. TSLP is a member of a class of epithelial cytokines, also including IL-25 and IL-33, commonly referred to as alarmins. TSLP is primarily produced by epithelial cells, especially in the lung, gastrointestinal tract and skin.

Webull offers UpStream Bio Inc. stock information, including NASDAQ: UPB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, UPB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading UPB stock methods without spending real money on the virtual paper trading platform.